EBR SYSTEMS INC. (ASX: EBR)
Health care · News and insights
Price unavailable
Latest EBR announcements
Announcement Insights
EBR Raises A$150 Million As WiSE Implant Pace Softens And Safety Precautions Tighten
EBR completed a A$150 million capital raising as WiSE commercial implants reached 157 in the third quarter of 2026, but September cases fell to about half the July–August average; the company said early fourth-quarter results were positive following a US sales-team realignment. From 1 October, Medicare inpatient base payment rates for eligible procedures rose by approximately 58% and 93% across the relevant categories, with a national coverage decision expected in early December. EBR also updated ultrasound precautions after 17 reported cases of inappropriate pacing among 586 implanted patients, including one death, while saying implants continued without interruption and no device returns, removals or reprogramming were required.
Updated 16 Nov 2026, 01:38 PM Sydney time
Sources
Change of Director's Interest NoticeCustomers Notification - Updated Ultrasound PrecautionsQ3 2026 Quarterly Activity Report and Form 10-Q SubmissionInvestor WebinarInvestor Webinar - UpdatedEBR to Present at Canaccord Genuity ForumComments
2026-11-16 · Health care
EBR: $0.155 +0.00% · MC: $113M
EBR Systems director Bronwyn Evans reported on-market purchases that increased her joint holding with Peter Douglas Gordon to 1.7 million CDIs from about 1.13 million. The notice also records Evans’s direct options, which were unchanged.
Updated 2026-11-16 13:29
Sources
Change of Director's Interest NoticeComments
2026-11-12 · Health care
EBR: $0.170 +0.00% · MC: $113M
EBR Systems is notifying healthcare providers of updated ultrasound precautions for patients with its WiSE cardiac pacing system after reports of inappropriate pacing, including one death. The company identified 17 reported events among 586 implanted patients, but cautioned that those figures do not represent the probability of an event during an individual examination. The correction does not require devices to be returned, removed or reprogrammed, and commercial implants continue. EBR said it does not expect the forthcoming labelling update to materially affect its commercial activities or financial position.
Updated 2026-11-12 10:45
Sources
Customers Notification - Updated Ultrasound PrecautionsComments
2026-11-10 · Health care
EBR: $0.165 +22.22% · MC: $113M
EBR Systems said third-quarter WiSE implant volumes fell below expectations, with September activity approximately half the average monthly level in July and August. The company is recruiting a new chief commercial officer and reported positive early results in the fourth quarter following a realignment of its US commercial team. Medicare reimbursement for eligible procedures has increased, while a proposed national coverage decision is expected in early December. EBR expects approval of its new manufacturing site by year-end, subject to FDA review, and held approximately A$137 million in cash and securities at the end of September after completing a A$150 million capital raising.
Updated 2026-11-10 11:03
Sources
Q3 2026 Quarterly Activity Report and Form 10-Q SubmissionInvestor WebinarInvestor Webinar - UpdatedComments
2026-11-03 · Health care
EBR: $0.115 +0.00% · MC: $113M
EBR Systems says management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on November 11.
Updated 2026-11-03 10:43
Sources
EBR to Present at Canaccord Genuity ForumComments
Comments